Curanex is a pre-revenue, clinical-stage pharmaceutical company developing a single botanical drug candidate, Phyto-N, for inflammatory diseases. Phyto-N is a proprietary botanical extract derived from a medicinal plant used in Chinese traditional medicine. The lead target indication is moderate-to-severe ulcerative colitis, where Curanex aims to position Phyto-N as an orally administered alternative to injectable biologics like Humira and Entyvio. Curanex argues Phyto-N's differentiation lies in a multi-target mechanism that may simultaneously modulate multiple inflammatory pathways, unlike approved biologics that typically block a single cytokine or receptor. All development to date has been preclinical. Curanex completed GMP manufacturing of a pilot batch in February 2026 and a 28-day toxicology study in March 2026, and is targeting an IND submission to the FDA for ulcerative colitis in Q4 2026, with Phase 1 trials planned in Australia. Beyond ulcerative colitis, Curanex has conducted preclinical studies in atopic dermatitis, COVID-19, diabetes, NAFLD/NASH, and gout, and plans to pursue these secondarily, potentially through licensing rather than internal development. The company also has a longer-term goal of isolating active compounds within Phyto-N to develop conventional small molecule drugs. Curanex went public on Nasdaq in August 2025 under the ticker CURX, and relies entirely on equity financing, with commercialization potentially many years away.